logo
  

Fulcrum Therapeutics: FDA Grants Orphan Drug Designation To Losmapimod

Fulcrum Therapeutics, Inc. (FULC) announced the FDA has granted Orphan Drug Designation to losmapimod, a selective p38a/ß mitogen activated protein kinase inhibitor for the treatment of facioscapulohumeral muscular dystrophy. The company is currently conducting Phase 2 trials investigating the safety, tolerability, and efficacy of losmapimod to treat the root cause of facioscapulohumeral muscular dystrophy.

The company also announced the issuance of a U.S. patent with claims covering the use of other p38 kinase inhibitors for the treatment of facioscapulohumeral muscular dystrophy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT